Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
Find out how Sensorion’s SENS-601 regulatory push could reshape GJB2 hearing loss gene therapy and clinical strategy.
Pharma & Biotech
Pharma & Biotech
How Sensorion’s SENS-501 data could reshape gene therapy for congenital hearing loss treatment
Sensorion reports promising gene therapy data for congenital deafness. Discover what it means for hearing loss treatment and future clinical breakthroughs.